A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
The company’s stock slides 12% on fears that the goalposts in its all-important Unity-CLL trial are being moved.
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.
The company’s plan to cut jobs and look at external deals could be a sign that it is becoming more like other big pharmas.
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.